共 50 条
- [42] Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis Drug Safety, 2019, 42 : 617 - 632
- [47] Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2006, 3 (07): : 390 - 407
- [49] Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis Nature Clinical Practice Gastroenterology & Hepatology, 2006, 3 : 390 - 407